Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: Mark A. Perazella Clear advanced filters

  • Acute kidney injury (AKI) is a growing problem in hospitalized patients and is associated with adverse outcomes. Recognizing renal injury earlier—at the stage of 'incipient AKI'—may enable renoprotective strategies to be initiated at a time when more kidney tissue is salvageable. In this article, the authors propose three strategies that may preserve kidney function and minimize further kidney injury in patients with 'incipient AKI'.

    • Mark A. Perazella
    • Steven G. Coca
    Reviews
    Nature Reviews Nephrology
    Volume: 9, P: 484-490

  • Designer drugs—synthetic psychoactive compounds with similar structures and activities to scheduled or controlled chemical compounds—are increasingly available. In this Review, Perazella and Luciano discuss the health burden associated with recreational use of these 'legal highs', and highlight the need for clinicians to be aware of the potential for adverse effects, including acute kidney injury, obstructive nephropathy and hyponatraemia.

    • Randy L. Luciano
    • Mark A. Perazella
    Reviews
    Nature Reviews Nephrology
    Volume: 10, P: 314-324

  • Here, the authors provide guidance on the prevention, diagnosis and management of anticancer therapy nephrotoxicity in adult patients. They also define a research agenda focused on preventing and mitigating anticancer therapy toxicity, maximizing early detection of nephrotoxicity and enabling optimal drug dosing in patients with kidney disease.

    • Amanda DeMauro Renaghan
    • Marlies Ostermann
    • Mitchell H. Rosner
    Reviews
    Nature Reviews Nephrology
    P: 1-18

  • Nephrotoxin-induced acute kidney injury (AKI) is a considerable risk among hospitalized children. The development and use of a proactive, nephrotoxin screening system seems to have led to a significant improvement in AKI rates in one children's hospital, suggesting that such systems might have broader implications for patient care.

    • Mark A. Perazella
    • F. Perry Wilson
    News & Views
    Nature Reviews Nephrology
    Volume: 12, P: 511-512

  • Acute interstitial nephritis (AIN) is a common cause of acute kidney injury. The most common etiology of AIN is drug-induced disease, which results from a reaction to certain medications. Multiple classes of drugs can induce AIN, resulting in a range of clinical presentations and laboratory findings. This Review describes the clinical features of drug-induced AIN, with a particular focus on the different features that are induced by different agents. The pathology, diagnosis and management of drug-induced AIN are also discussed.

    • Mark A. Perazella
    • Glen S. Markowitz
    Reviews
    Nature Reviews Nephrology
    Volume: 6, P: 461-470

  • Highly active antiretroviral therapy (HAART) has a variety of adverse renal effects. Patients receiving HAART can develop acute kidney injury, which can progress to chronic kidney disease. HAART also contributes indirectly to kidney disease by increasing the risk of diabetes and hypertension. This Review describes the epidemiology, mechanisms and diagnosis of HAART-related kidney damage, with an emphasis on the preventive management of risk factors such as intravascular volume depletion and pharmacological interactions.

    • Hassane Izzedine
    • Marianne Harris
    • Mark A. Perazella
    Reviews
    Nature Reviews Nephrology
    Volume: 5, P: 563-573

  • Immune checkpoint inhibitors are increasingly used as anti-cancer treatments; however, their use can be associated with the development of immune-related adverse events, including acute kidney injury. This Review describes the symptoms, biochemical signs and possible underlying mechanisms of immune checkpoint inhibitor-associated acute kidney injury, and proposes an approach to its diagnosis and management.

    • Ben Sprangers
    • David E. Leaf
    • Mark A. Perazella
    Reviews
    Nature Reviews Nephrology
    Volume: 18, P: 794-805

  • Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in cancer therapy; however, these agents can induce immune-related adverse events (irAEs) in off-target organs. This Review describes the mechanism of action of ICI therapies and how these agents induce irAEs in the kidney and heart.

    • Krishna Sury
    • Mark A. Perazella
    • Anushree C. Shirali
    Reviews
    Nature Reviews Nephrology
    Volume: 14, P: 571-588